Positive results for UBC® Rapid in an Austrian study | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

August 2017

Positive results for UBC® Rapid in an Austrian study

International Journal of Medical Sciences has published an Austrian study with UBC® Rapid performed at the Department of Urology, Medical University of Innsbruck. Urinary samples were analyzed by cytology, UBC® Rapid and NMP22 BladderChek® test.

The results from this study coincide very well with the results from previous reported studies, with a very high UBC® Rapid sensitivity for in particular high grade bladder cancer tumors compared to both cytology and NMP22 BladderChek® test.

Bladder cancer is a common and resource-intensive cancer. Patients often need extensive and long-term follow-up after primary diagnosis. Methods for early detection and regular follow-up are of great importance.

Cystoscopy, a procedure in which the inside of the bladder is examined using an optical instrument, is the most commonly used method for detection of bladder cancer.

The use of urine-based markers in evaluation of bladder cancer is an interesting approach since the tumors are constantly in contact with urine. UBC® Rapid is a non-invasive test detecting cytokeratin 8 and 18 fragments released from urothelial cells into the urine as markers for bladder cancer. UBC® Rapid combined with a reader is the first quantitative point-of-care system for bladder cancer, enabling risk stratification in a point-of-care setting.

Jerker Swanstein new Chairman of the Board of Directors

The annual general meeting, held 28th of May 2019, re-elected Jerker Swanstein, Per-Anders Abrahamsson and Carsten Olsson, and elected Malin Ruijsenaars and Eva Sjökvist Saers as new members of the Board of Directors. During the statutory meeting held 28th of May 2019 Jerker Swanstein was selected as new Chairman of the Board of Directors.

Information from the Annual General Meeting

The Annual General meeting was held on the 28th of May 2019.

IDL Biotech

Skip this intro